Product logins

Find logins to all Clarivate products below.


Cybercitizen Health Europe 2015 Strategic Insight Report – How can pharma reach consumers choosing between different brand-name drugs?

EU consumers who use online resources to choose between different brand-name drugs are much more likely to advocate for themselves at the point-of-care. With this in mind, EU pharma marketers must think about what website features and content to provide for consumers that are going online to choose treatment options; this Strategic Insight covers what pharma marketers need to know.

Questions answered in this report:
How can pharma reach consumers choosing between different brand-name drugs?

Related Multichannel Engagement Reports

Report
Patient Omnichannel Insights | Cybercitizen Health | 2023 | US | Pneumococcal Vaccines
Patient Omnichannel Insights | Cybercitizen Health | 2023 | US | Pneumococcal Vaccines Our 2023 study among patients and caregivers provides detailed insights and recommendations on the…
Report
Patient Omnichannel Insights | Cybercitizen Health | 2023 | US | HPV Vaccines
Patient Omnichannel Insights | Cybercitizen Health | 2023 | US | HPV Vaccines Our 2023 study among patients and caregivers provides detailed insights and recommendations on the information-…
Report
Patient Multichannel Insights | 2022 | Cybercitizen Health | Colombia | Segmentation
Patient Multichannel Insights | 2022 | Cybercitizen Health | Colombia (Segmentation Data Tables)
Report
Patient Multichannel Insights | 2022 | Cybercitizen Health | US | Multiple Myeloma | Segmentation
Patient Multichannel Insights | 2022 | Cybercitizen Health | US | Multiple Myeloma (Segmentation Data Deck)
Report
Patient Multichannel Insights | 2022 | Cybercitizen Health | US | AML VS CLL VS MM | Segmentation Data
Patient Multichannel Insights | 2022 | Cybercitizen Health | US | AML VS CLL VS MM (Segmentation Data Comparison Table)